On October 7, Sermo, a social community platform for medical doctors, launched the outcomes of a survey on healthcare suppliers’ opinions in regards to the newest Advisory Committee on Immunization Practices (ACIP) suggestions. Responses revealed each confidence and concern, significantly concerning COVID-19.
Healthcare Innovation’s Mark Hagland lately reported on the ACIP’s conferences in September to hammer out vaccine insurance policies, which turned chaotic. The Committee finally voted—amid sturdy opposition from some members—to make a number of adjustments to vaccine schedules, Hagland reported. It voted to not enable a federal vaccine program to cowl the price of a mixture vaccine that protects towards measles, mumps, rubella, and varicella, often known as chickenpox, whereas indefinitely suspending a vote on hepatitis B vaccination. Moreover, it voted to maneuver away from common vaccination utilizing mRNA vaccines for COVID-19 prevention.
Sermo reported that one in 4 clinicians struggled to interpret the brand new steerage. Pediatricians stood out specifically, with greater than half reporting confusion, and one in 5 describing the suggestions as very complicated. Three areas recognized as issues had been COVID-19 (77 p.c), MMR/Varicella (58 p.c), and HepB (55 p.c).
Most survey respondents supported the ACIP’s choices, with 29 p.c strongly agreeing and 43 p.c considerably agreeing. Nonetheless, the information revealed a extra nuanced image when damaged down by specialty. Pediatricians had been extra skeptical, with almost 70 p.c disagreeing to a point.
When it got here to COVID-19 vaccine suggestions, six in ten respondents mentioned that the brand new suggestions had been grounded in real-world scientific proof. Suppliers strongly favored federal tips (63 p.c) over state-by-state decision-making.
The ACIP additionally up to date its suggestions for childhood vaccines, together with recommendation that youngsters beneath age 4 obtain separate MMR and varicella photographs as an alternative of the mixed MMRV vaccine. On this, suppliers had been divided, with 60 p.c agreeing and 40 p.c disagreeing.
Sermo surveyed 243 healthcare professionals – together with US PCPs, pharmacists, pediatricians, OB/GYNs, and NP/PAs.
